Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Inc (NQ: TVTX )

18.50 +0.25 (+1.40%)
Streaming Delayed Price Updated: 11:00 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Preview For Travere Therapeutics
Via Benzinga
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics
Via Benzinga
Where Travere Therapeutics Stands With Analysts
Via Benzinga
What's Going On With Travere Therapeutics Stock?
Travere Therapeutics, Inc. (NASDAQ: TVTX) shares are trading higher Tuesday. 
Via Benzinga
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in Japan 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2024 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Inc. (NASDAQ: TVTX) Near the Top of Equities by Percentage Gain on 12/5
Via Investor Brand Network
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Preview: Travere Therapeutics's Earnings
Via Benzinga
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
Exposures Product Safety
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026 
From Travere Therapeutics, Inc.
Via GlobeNewswire
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Moves Lower; AutoZone Profit Tops Views
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly lower, with the Dow Jones index falling more than 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.